<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395365</url>
  </required_header>
  <id_info>
    <org_study_id>17/0894</org_study_id>
    <nct_id>NCT04395365</nct_id>
  </id_info>
  <brief_title>Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis</brief_title>
  <acronym>ASEPTIC</acronym>
  <official_title>Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, interventional, double-blind, placebo-controlled, parallel-arm, phase 3,&#xD;
      randomised controlled trial to evaluate the use of co-trimoxazole as primary prophylaxis for&#xD;
      spontaneous bacterial peritonitis to improve overall survival&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2019</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>The maximum possible period of follow up will be 48 months (assuming a recruitment period of 30 months and 18 months treatment period for final patient recruited)</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spontaneous Bacterial peritonitis</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Time to first incidence of spontaneous bacterial peritonitis (SBP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admissions</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Hospital admission rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C. difficile-associated diarrhoea</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Incidence of C. difficile-associated diarrhoea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections other than spontaneous bacterial peritonitis with hospital admission</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Incidence of infections other than spontaneous bacterial peritonitis with hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cirrhosis related events</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Incidence of other cirrhosis related events (e.g. variceal haemorrhage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal dysfunction</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Incidence of renal dysfunction with creatinine &gt;133 μmol/L (1.5mg/dL) at any point during hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-microbial resistance</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Incidence of anti-microbial resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver transplantation</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Incidence of liver transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver disease assessed by increase in MELD score</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Progression of liver disease assessed by increase in MELD score between baseline and end of trial follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and treatment-related serious adverse events</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Safety and treatment-related serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Treatment adherence (assessed by MARS questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Health-related quality of life assessed using EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health and social care</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Health and social care resource use assessed using Hospital Episode Statistics (HES) database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean incremental cost per quality adjusted life year gained (QALY)</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Mean incremental cost per quality adjusted life year gained (QALY)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of resolution of ascites with diuretic treatment not required for 6 months</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Incidence of resolution of ascites with diuretic treatment not required for 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transjugular intrahepatic portosystemic shunt (TIPS) insertion</measure>
    <time_frame>Minimum period of 18 months from randomisation</time_frame>
    <description>Incidence of Transjugular intrahepatic portosystemic shunt (TIPS) insertion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">432</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <arm_group>
    <arm_group_label>Co-trimoxazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-trimoxazole, 960mg capsule oral tablet, to be taken daily for 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 960mg capsule oral tablet, to be taken daily for 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-Trimoxazole 960Mg Dispersible Tablet</intervention_name>
    <description>Antibiotic prophylaxis of Spontaneous Bacterial Peritonitis</description>
    <arm_group_label>Co-trimoxazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients with Child-Pugh Class B or C cirrhosis and presence of ascites requiring any&#xD;
             diuretic treatment or at least 1 or more paracentesis within 3 months prior to&#xD;
             enrolment.&#xD;
&#xD;
          2. Patient at least 18 years of age&#xD;
&#xD;
          3. Documented informed consent to participate&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patients with current or previous Spontaneous Bacterial Peritonitis (defined as&#xD;
             ascitic polymorphonuclear (PMN) cell count &gt;250/mm3 with either positive or negative&#xD;
             ascitic fluid culture without evident intra-abdominal surgically treatable source of&#xD;
             infection. A white cell count &gt;500 cell/mm2 or positive microbial culture may be&#xD;
             considered as evidence of previous SBP if the site PI considers this was in the&#xD;
             context of a likely clinical diagnosis of SBP).&#xD;
&#xD;
          2. Patients receiving palliative care with an expected life expectancy of &lt;8 weeks&#xD;
&#xD;
          3. Allergic to co-trimoxazole, trimethoprim or sulphonamides&#xD;
&#xD;
          4. Pregnant or lactating mothers&#xD;
&#xD;
          5. Patient enrolled in a clinical trial of investigational medicinal products (IMPs) that&#xD;
             would impact on their participation in the study&#xD;
&#xD;
          6. Patients with serum potassium (&gt;5.5 mmol/L) related to pre-existing kidney disease&#xD;
             which cannot be reduced*&#xD;
&#xD;
          7. Patients receiving antibiotic prophylaxis (except for rifaximin)*&#xD;
&#xD;
          8. Patients with long-term ascites drains*&#xD;
&#xD;
          9. Women of child-bearing potential and males with a partner of child-bearing potential&#xD;
             without effective contraception for the duration of trial treatment&#xD;
&#xD;
         10. Patients with pathological blood count changes&#xD;
&#xD;
               1. Patients with haemoglobin (Hb) &lt;70g/L*&#xD;
&#xD;
               2. Granulocytopenia defined as absolute neutrophil counts of less than 500 cells per&#xD;
                  microliter*&#xD;
&#xD;
               3. Severe thrombocytopenia with a platelet count &lt;30 x109 /L*&#xD;
&#xD;
         11. Patients with severe renal impairment, with eGFR &lt;15 ml/min*&#xD;
&#xD;
         12. Patients with skin conditions: exudative erythema multiform, Stevens-Johnson syndrome,&#xD;
             toxic epidermal necrolysis and drug eruption with eosinophilia and systemic symptoms&#xD;
&#xD;
         13. Patients with congenital conditions: congenital glucose-6-Phosphate dehydrogenase&#xD;
             deficiency of the erythrocytes, haemoglobin anomalies such as Hb Köln and Hb Zürich&#xD;
&#xD;
         14. Patients with acute porphyria&#xD;
&#xD;
         15. Any clinical condition which the investigator considers would make the patient&#xD;
             unsuitable for the trial.&#xD;
&#xD;
               -  It is common for these investigations to change in patients with cirrhosis and&#xD;
                  long-term ascitic drains may be removed. Patients can be re-screened for&#xD;
                  eligibility if this occurs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Gear</last_name>
    <phone>02076705748</phone>
    <email>david.gear.16@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marisa Chau</last_name>
    <email>m.chau@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Free hospital</name>
      <address>
        <city>Hampstead</city>
        <state>London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alistair O'Brien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

